Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
2022 Midyear Review: Non–Small-Cell Lung Cancer
2022 Oncology Biosimilar Guide to Patient Support Services
2022 Breast Cancer Guide to Patient Support Services
Browse By Topic
Practice Management
Financial Management
Reimbursement
Health Policy
Quality Care
ICD Codes
Survivorship
FDA Approvals, News & Updates
In the News
Guide to Patient Support Services
Index
Introduction
2023 Spotlight: Amgen
Conference Correspondent
ASCO 2022 - Wrap Up
NSCLC IO 2022 - Midyear Review
SABCS 2021 Wrap-Up
Dual IO 2021 Year in Review
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Rapid Reactions
In the News
Quick Quiz
Multiple Myeloma Monthly Minutes
Melanoma Monthly Minutes
Press Releases
Women's Health Monthly Minutes
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes
Issues
2019
February 2019, Vol 9, No 2
February 2019, Vol 9, No 2
What Drives Patient Preferences When Facing Financial Toxicity?
By
Chase Doyle
Financial Toxicity
The economic burden caused by cancer and its treatment affects more than the patient’s bank account. As studies have shown, financial toxicity can lead to reduced quality of life, compromise treatment, and worsen clinical outcomes, and the associated devastation can extend to caregivers as well.
Read Article ›
Weight-Loss Intervention in Women with Breast Cancer Works Only with Adherence
By
Phoebe Starr
Breast Cancer
San Antonio, TX—An interim analysis of a randomized clinical trial showed that a lifestyle intervention aimed at weight loss achieved approximately a 1-kg weight loss in patients with early breast cancer who received chemotherapy, whereas patients in the control group gained approximately 1 kg over the course of the study.
Read Article ›
To Risk or Not to Risk? Or Is Risk Contracting Too Risky?
By
Dawn Holcombe, MBA, FACMPE, ACHE
From the Editor
The word on the street is that value-based, or risk-based, oncology contracts for physicians are the inevitable wave of the future. But are they?
Read Article ›
The Quality-Cost Connection in Cancer Care: Lessons from Oncology Practices in Washington State
By
Meg Barbor, MPH
Quality Care
Although many quality measures exist in oncology, few efforts have been undertaken to prioritize, measure, and report quality and costs for an entire region. A recent multiyear, multistakeholder effort to characterize quality of care and costs for Washington State oncology practices revealed that increased quality may be associated with a reduced cost of care in oncology.
Read Article ›
Supervised Exercise During Chemotherapy Improves Cardiovascular Function in Women with Breast Cancer
By
Phoebe Starr
Breast Cancer
A 12-month supervised exercise program improved cardiovascular function in women receiving adjuvant chemotherapy for breast cancer, including anthracyclines and taxanes. These results of a randomized clinical trial were presented at the 2018 San Antonio Breast Cancer Symposium.
Read Article ›
Researchers Identify First Mutation to Explain Resistance to Venetoclax
By
Phoebe Starr
Leukemia
Read Article ›
Patient-Reported Physical Symptoms More Likely to Be Addressed by Oncologists Than Depression or Anxiety
By
Meg Barbor, MPH
Symptom Management
Read Article ›
Pathologic Complete Response to Neoadjuvant Chemotherapy May Guide Escalation and De-escalation Treatment Strategies in Localized Breast Cancer
By
Phoebe Starr
Breast Cancer
Read Article ›
First-Line Ibrutinib Improves Outcomes Compared with Current Standard of Care in Older Patients with Chronic Lymphocytic Leukemia
By
Wayne Kuznar
Leukemia
Read Article ›
Explosive Development of BCMA CAR T-Cell Therapy for Multiple Myeloma
By
Phoebe Starr
Multiple Myeloma
Read Article ›
Do No Financial Harm: How to Improve Cost Transparency in Cancer Care
By
Chase Doyle
Financial Toxicity
Read Article ›
View the Latest Issue of OPM
Read Issue
Top Trending Articles
1.
Molecular Characteristics Increasingly Define Adult Gliomas
By
William King
2.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
By
William King
3.
Optimal Systemic Therapy for Renal Cell Carcinoma Is Still Evolving
By
William King
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
2022 Midyear Review: Non–Small-Cell Lung Cancer
2022 Oncology Biosimilar Guide to Patient Support Services
2022 Breast Cancer Guide to Patient Support Services
Browse By Topic
Practice Management
Financial Management
Reimbursement
Health Policy
Quality Care
ICD Codes
Survivorship
FDA Approvals, News & Updates
In the News
Guide to Patient Support Services
Index
Introduction
2023 Spotlight: Amgen
Conference Correspondent
ASCO 2022 - Wrap Up
NSCLC IO 2022 - Midyear Review
SABCS 2021 Wrap-Up
Dual IO 2021 Year in Review
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Rapid Reactions
In the News
Quick Quiz
Multiple Myeloma Monthly Minutes
Melanoma Monthly Minutes
Press Releases
Women's Health Monthly Minutes
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes